Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW427353 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW427353 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: \- Diagnosis of IBS which meets the Rome II criteria, screening pain score to be \> 1.5 (0= no pain, 4 = very severe pain) Exclusion Criteria: * Subjects not meeting the Rome II criteria for the diagnosis of IBS * Subjects with no stool for 7 days during the screen
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
GW427353 is an investigational small molecule being studied for the treatment of Irritable Bowel Syndrome (IBS). It is in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in patients with IBS to assess its safety and efficacy.
GW427353 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's potential in treating Irritable Bowel Syndrome (IBS).
GW427353 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities for commercial use. The Phase 2 trial for GW427353 in Irritable Bowel Syndrome (IBS) has been completed.
GW427353 has one completed Phase 2 clinical trial registered under NCT00394186, titled "A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)." The trial enrolled 100 participants with IBS across Australia, France, and Germany. It was a randomized, double-blind study.
The molecular target and mechanism of action for GW427353 have not been disclosed in available information. The drug is being studied for its potential effects in treating Irritable Bowel Syndrome (IBS), but its specific biological pathway remains undisclosed.